Form 4: Intuitive Surgical CEO Awarded 7,640 Restricted Stock Units

Intuitive Surgical, Inc. has disclosed a grant of 7,640 Restricted Stock Units to its Chief Executive Officer, David J. Rosa, as part of his compensation.

Summary

• David J. Rosa, Chief Executive Officer and Director of Intuitive Surgical, Inc. (ISRG), was granted 7,640 Restricted Stock Units (RSUs).
• The transaction date for this grant was July 10, 2025.
• Each RSU represents a contingent right to receive one share of Intuitive Surgical common stock.
• The RSUs will vest 25% on the first anniversary of the grant date and annually thereafter, over a four-year period.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The document reports a routine executive compensation event (RSU grant) which is generally neutral but slightly positive as it aligns management incentives with shareholder interests.

Positives

• The grant of Restricted Stock Units to the CEO aligns management's long-term interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent compensation structure.

Risks

• The issuance of new shares upon vesting of RSUs could lead to a minor dilution of existing shareholder equity over time.

Future Outlook

The vesting schedule of the granted Restricted Stock Units over a four-year period indicates a long-term commitment of the CEO to the company's performance and future growth.

Industry Context

Executive compensation, particularly through equity grants like RSUs, is a standard practice across the medical device and technology sectors. This grant is consistent with typical compensation structures designed to incentivize long-term performance and align executive interests with shareholder value in the surgical robotics industry.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a common practice across publicly traded companies, including those in the medical technology sector like Intuitive Surgical.
• The four-year vesting schedule is a standard duration for equity grants, aiming to retain executives and incentivize sustained performance, comparable to practices at companies such as Medtronic or Stryker.

Related Party Transactions

• The grant of 7,640 Restricted Stock Units to David J. Rosa, the Chief Executive Officer and Director, constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: The grant aligns the CEO's financial interests with long-term shareholder value, but also introduces potential minor dilution upon vesting.
• Employees: This disclosure pertains specifically to executive compensation and does not directly impact the broader employee base's compensation or benefits.

Next Steps

• The granted Restricted Stock Units will begin vesting 25% on the first anniversary of the grant date (July 10, 2026) and annually thereafter over a four-year period.

Key Dates

Keywords

Intuitive Surgical, ISRG, Restricted Stock Units, RSU, Executive Compensation, SEC Form 4, David J. Rosa, CEO, Stock Grant, Corporate Governance